Rasagiline Mesylate

CHEMBL1201142 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

267.4 g/mol

LogP

—

Phase

4

The mesylate salt formulation of rasagiline used to manage the motor symptoms of Parkinson's disease by preventing the breakdown of dopamine in the brain. It helps improve movement control and reduce the wearing-off effects associated with levodopa therapy.

Moleküler Ağırlık

267,3500 g/mol

TPSA

74,80 Å²

Terapötik Alanlar

Alzheimer's Disease Parkinson's Disease Schizophrenia Major Depressive Disorder

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C#CCN[C@@H]1CCc2ccccc21.CS(=O)(=O)O

InChI

InChI=1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/m1./s1

Molecular Formula

C13H17NO3S

HBD / HBA

2 / 4

Döndürülebilir Bağlar

2

Ağır Atomlar

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The mesylate salt formulation of rasagiline used to manage the motor symptoms of Parkinson's disease by preventing the breakdown of dopamine in the brain. It helps improve movement control and reduce the wearing-off effects associated with levodopa therapy.

Yes, Rasagiline Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201142. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3052775. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Rasagiline Mesylate PillFYI'da

Yapı

Hızlı Veriler

Formül: C13H17NO3S
Eş Anlamlılar: 2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.